Table 5.

Baseline Factors Association with Development of Central-Involved Macular Edema, and Development or Progression of Non-central Involved Macular Edema at 16 Weeks

	Central-Involved Macular Edema			Non-central Involved Macular Edema
Parameters	N/total (%)	95%CI	P Value*	N/total (%)	95%CI	P Value*
Visual Acuity Group at Baseline – E-ETDRS Letter Score (%)			0.06			0.11
≥69 (20/40 or better)	10/144 (7%)	(3-12%)		11/140 (8%)	(4-14%)
68-54 (20/50 to 20/80)	12/91 (13%)	(7-22%)		7/78 (9%)	(4-18%)
53-39 (20/100 to 20/160)	5/23 (22%)	(7-44%)		3/21 (14%)	(3-36%)
≤38 (20/200 or worse)	3/18 (17%)	(4-41%)		3/10 (30%)	(7-65%)
Any History of DME Treatment (%)			<0.001			<.001
Yes	24/123 (20%)	(13-28%)		19/105 (18%)	(11-27%)
No	6/153 (4%)	(1-8%)		5/144 (3%)	(1-8%)
History of PRP (%)			0.50			0.31
Yes	9/68 (13%)	(6-24%)		8/59(14%)	(6-25%)
No	21/208 (10%)	(6-15%)		16/190 (8%)	(5-13%)
Diabetic Retinopathy Severity (%)			0.06			0.08
Microaneurysms only	2/54 (4%)	(0.04-13%)		1/54 (2%)	(0-10%)
Mild/moderate NPDR	12/128 (9%)	(4-16%)		12/115 (10%)	(6-18%)
Severe NPDR	2/14 (14%)	(2-43%)		1/9 (11%)	(0-48%)
PDR and/or prior scatter  laser photocoagulation	14/80 (18%)	(10-28%)		10/71 (14%)	(7-24%)
HbA1c (%)			0.83			1.00
≥8.0	8/87 (9%)	(4-17%)		8/79 (10%)	(4-19%)
<8.0	19/177 (11%)	(7-16%)		15/159 (9%)	(5-15%)
Age Group (%)			0.18			0.28
≥65	12/145 (8%)	(4-14%)		10/134 (7%)	(4-13%)
<65	18/131 (14%)	(8-21%)		14/115 (12%)	(7-20%)
Gender (%)			0.44			1.00
Women	15/159 (10%)	(5-15%)		14/147 (10%)	(5-15%)
Diabetes Type (%)			0.27			0.13
Type I	1/34 (3%)	(0-15%)		0/29 (0%)	(0-12%)
Type II	27/225 (12%)	(8-17%)		22/204 (11%)	(7-16%)
Uncertain	2/17 (12%)	(1.4-36%		2/16 (13%)	(2-38%)

E-ETDRS= Electronic early treatment diabetic retinopathy study; DME=diabetic macular edema; PRP=panretinal photocoagulation; NPDR=non-proliferative diabetic retinopathy; PDR=proliferative diabetic retinopathy; HbA1c=hemoglobin A1c

^*Fisher Exact Test